Israeli inhalation therapy is being tested against the cytokine storm

–

–

–

EXO-CD24 is just one of over 420 drug developments against COVID to date, it has not passed the important phase 3 clinical trial

Israeli experimental therapy EXO-CD24 is another hope for the treatment of COVID and reduction of mortality from severe cases. The scientific study has been applied to a small number of people, but according to press releases from phase 1 and 2 clinical trials, it prevents a fatal outcome. In that

therapy is

apply 5 days

once a day

by inhalation for

for a few minutes

Direct delivery to the lungs will help prevent a cytokine storm – the overreaction of the immune system fighting the new coronavirus, the creators expect.

The “father” of the drug, Prof. Nadir Arber, is a gastroenterologist and director of the Integrated Center for Cancer Prevention, who has been working on the topic of cancer treatment for 25 years. Together with researcher Sheeran Shapira, he uses a “module” of these efforts to control immune responses through a natural protein in the body. In a broad sense, the idea of ​​precision therapies materializes.

The drug is directed directly at the target of the virus – the lungs. This gives it the advantage of being applied topically, but acting broadly and without side effects, according to Prof. Arber. The team uses exosomes as carriers – small extracellular capsules (vesicles). They can carry the CD24 protein – studied for decades by cancer center scientists – into the lungs. It is believed to play a key role in many cancers. It also intervenes in controlling the growth of immune T cells.

CD24 is located on the cell surface and has a proven role in regulating the immune system. In this case, the aim is to prevent the body from overreacting,

to tame

unjustified

force with which

the cells are

pounce on

the unknown enemy

After the first trial on 30 people in Tel Aviv, the experimental therapy received permission for a clinical trial on 90 people in Greece with the co-sponsorship of a pharmaceutical company. The results have not been published, the news refers to a press release. According to him, “the results are promising.” Prof. Arber has been quoted by many media outlets as saying that the drug will be cheap, fast to produce and can meet the needs of the world in a short time.

However, experts point out that EXO-CD24 is only one of more than 420 drug developments against COVID to date. And it did not go through the 3rd phase of testing.

– .